Slide 1 Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III…

Slide 1 Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial…

Slide 1 E1308:A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell…

Slide 1 Highlights of the Day:Central Nervous System Tumors Presented By Michael Prados at 2014 ASCO Annual Meeting Slide 2 Presented By Michael Prados at 2014 ASCO Annual…

Slide 1 Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial…

Slide 1 Prevention of Early Menopause Study(POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone receptor-negative…

Slide 1 Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III…

Slide 1 Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab…

Slide 1 Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented By…

Slide 1 A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent…